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Abstract
Background: Whereas the antimicrobial peptides hBD-2 and -3 are related to inflammation, the
constitutively expressed hBD-1 might function as 8p tumour suppressor gene and thus play a key
role in control of transcription and induction of apoptosis in malignant epithelial tumours.
Therefore this study was conducted to characterise proteins involved in cell cycle control and host
defence in different benign and malignant salivary gland tumours in comparison with healthy salivary
gland tissue.
Methods: 21 paraffin-embedded tissue samples of benign (n = 7), and malignant (n = 7) salivary
gland tumours as well as healthy (n = 7) salivary glands were examined immunohistochemically for
the expression of p53, bcl-2, and hBD-1, -2, -3.
Results: HBD-1 was distributed in the cytoplasm of healthy salivary glands and benign salivary
gland tumours but seems to migrate into the nucleus of malignant salivary gland tumours.
Pleomorphic adenomas showed cytoplasmic as well as weak nuclear hBD-1 staining.
Conclusion: HBD-1, 2 and 3 are traceable in healthy salivary gland tissue as well as in benign and
malignant salivary gland tumours. As hBD-1 is shifted from the cytoplasm to the nucleus in
malignant salivary gland tumours, we hypothesize that it might play a role in the oncogenesis of
these tumours. In pleomorphic adenomas hBD-1 might be connected to their biologic behaviour
of recurrence and malignant transformation.
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Background
The majority of salivary gland tumours are benign. Malig-
nant salivary gland tumours are less frequent but occur in
15 to 32 percent of all patients. The most common point
of origin for salivary gland tumours is the parotic gland in
up to 80 percent of all cases [1].
Salivary gland tumours show a variety of different mor-
phologic features which complicate the exact histomor-
phological diagnosis. They might be subdivided into
salivary gland tumours with a) myoepithelial compo-
nents, b) basaloid components, c) epithelial components,
d) lymphatic components and e) pleomorphic adenomas
[2].
In the investigation of the development of salivary gland
tumours as well as in the prediction of their clinical course
and possible treatment options, molecular biology has
moved into the centre of tumour research. In this context
proliferation associated antigens as Ki-67, proto-onco-
genes as bcl-2, tumour suppressor genes as p53 or p21 and
the overexpression of growth-factor binding receptors as
HER-2 have been identified as important factors in the
malignant progression of these tumours. [3].
Defensines as hBD-1, -2, -3 are positively charged peptides
with molecular weights ranging from 3.5 to 6.5 kDa. Their
ability to disintegrate membranes is responsible for their
antimicrobial potency against a number of gram-positive
and gram-negative bacteria as well as yeasts and certain
viruses. Defensins have been detected in different tissues
as the epithelia of the oral cavity, the gastrointestinal and
respiratory tract, the urinary tract and the vagina as well as
in salivary glands [4-7]. HBD-2 and -3 have been detected
in the joint cartilage of patients with osteoarthritis thus
being involved in the repair processes after cartilage dam-
age in the cause of inflammation [8].
As defensins have been detected in the submandibular
glands of patients with oral carcinomas [9] they might
also play a role in tumour immunity and disintegration of
tumour cells.
Whereas hBD-2 and -3 seem to be related to inflamma-
tion, the constitutively expressed hBD-1 might be
involved in carcinogenesis. HBD-1 is located in a defensin
gene cluster on the short arm of chromosome 8. There was
a cancer specific loss of hBD-1 in 90% of renal clear cell
carcinoma and 82% of malignant prostate cancer,
whereas in benign epithelium the expression of hBD-1
was intact [10]. In oral squamous cell carcinomas of the
oral cavity we found a 50-fold decreased, but not com-
plete loss of human β-defensin-1 gene expression [11].
Therefore hBD-1 might function as 8p tumour suppressor
gene and thus play a key role in control of transcription
and induction of apoptosis in epithelial tumours [12].
This study was conducted to characterise proteins
involved in cell cycle control and host defence in different
benign and malignant salivary gland tumours in compar-
ison with healthy salivary glands.
Methods
In this study, 21 tissue samples of 7 patients with con-
firmed diagnosis of a benign, 7 patients with a malignant
salivary gland tumour and 7 healthy salivary glands were
investigated: 12 patients were of female and 9 patients
were of male gender. The average age at diagnosis was
53.8 years. The healthy salivary gland tissue was collected
from patients with head and neck tumours during the sur-
gical procedure of neck dissection; those patients were
neither irradiated nor received chemotherapy. Procedures
involving the human tissue sampling collection followed
a protocol approved by the ethical board of the University
of Bonn.
After formalin fixation the tissue samples were embedded
in paraffin and cut with a standard microtome (Reichert-
Jung, Heidelberg, Germany) into 2 μm sections. Tissues
for light microscopic evaluation were stained with Hema-
toxylin and Eosin (HE) and the diagnosis was confirmed
by a pathologist (HPF). Immunohistochemistry was per-
formed for p53, bcl-2, hBD-1, -2, and -3.
Immunohistochemistry
Formalinfixed, paraffin-embedded tissue sections were
used for immunohistochemical staining. After deparaffin-
ization and dehydration, the slides were washed in Tris-
buffered saline (TBS, Quartett GmbH, Berlin, Germany)
containing 0.1% BSA. Endogenous peroxidase activity
was quenched by incubating the slides in a solution of
700 μl H2O2 (30%) in 70 ml methanol. To perform anti-
gen retrieval, the sections were pretreated with pepsin
(0.4%) for 30 min at 37 °C. Blocking was done with nor-
mal serum. After incubation with primary antibody
against p53, bcl-2, hBD-1, -2, and -3 (hBD-1 and p53:
Biologo, Kronshagen, Germany; bcl-2: Quartett GmbH,
Berlin, Germany; hBD-2: Santa Cruz Biotechnology, Hei-
delberg, Germany; hBD-3: Gentaur, Aachen, Germany) at
room temperature for 60 min.
The slides were then washed in TBS buffer and the HRP-
conjugated secondary antibody (DAKO, Hamburg, Ger-
many) was added and the slides were incubated at room
temperature for 30 min. Afterwards the slides were
washed in TBS buffer and incubated with diamino benzi-
dine tetrahydrochloride (DAB) as substrate and counter-
stained with hematoxylin (Merck Eurolab, Dietikon,
Switzerland). Negative controls without primary antibody
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were included in each experiment to verify antibody spe-
cificity [13].
The immuno-staining for p53, bcl-2, and hBD-1, -2, and -
3 was analysed using a Zeiss Axio-Imager A.1 microscope
(Zeiss, Oberkochen, Germany). Tissue staining was
assessed by using + (weak positive), ++ (positive), or -
(negative).
To quantify the nuclear proportion, 100 cells per speci-
men were analysed for positive nuclear in comparison
with cellular immunostaining in consecutive fields.
Results
All tissue samples showed specific immunostaining. There
was positive immunostaining for the defensins hBD-1, -2
and -3 in all tissue samples: In the benign salivary gland
tumours (n = 7) and in the healthy salivary gland tissue (n
= 7) hBD-1 was located in the cytoplasm. In the three ple-
omorphic adenomas there was additionally weak nuclear
hBD-1 staining.
In the malignant tumours (n = 7) hBD-1 was located in
the nucleus. In two of the malignant tumours there was
additionally weak cytoplasmic hBD-1 staining. HBD-2
was detectable in the cytoplasm of the ducts in benign (n
= 7) and malignant (n = 7) tumours as well as in the
healthy tissue (n = 7). HBD-3 was located mostly in the
cytoplasm of all tissues, but in one adenoid cystic carci-
noma particularly in the nucleus as well.
P53 was positive in five of the malignant and two of the
benign salivary gland tumours. The positive p53-immu-
nostaining was very weak and occurred in two oncocyto-
mas.
Bcl-2 was detected only in three of the malignant, but in
six of the benign salivary gland tumours. There was no
correlation between p53 and bcl-2 immunostaining.
All results are summarised in table 1 and 2.
Fig. 1 shows the typical hBD-1 staining in an adenoid
cystic carcinoma in comparison with healthy salivary
gland tissue (fusion figure). Fig. 2 shows hBD-2 and Fig. 3
shows hBD-3 staining in adenoid cystic carcinomas
(below) in comparison with healthy salivary gland tissue
(above). Fig. 4 shows nuclear and cytoplasmatic hBD-1
staining in a pleomorphic adenoma.
Discussion
In the present study the protein expression of human
beta-defensins hBD-1, -2, -3, the tumour suppressor gene
p53 and the proto-oncogene bcl-2 was analyzed in
healthy salivary gland tissue in comparison with different
benign and malignant salivary gland tumours. The most
interesting finding indicated, that hBD-1 seems to be
shifted from the cytoplasm to the nucleus of the tumour
cells in malignant salivary gland tumours. Different
benign and malignant tumours were chosen, to demon-
strate that the translocation of hBD-1 was to be independ-
ent from the type of tumour.
HBD-1 is known to be constitutively expressed in epithe-
lial tissues [6], whereas hBD-2 and -3 are inducible by
inflammatory mediators as IL-1β. HBD-2 and -3 are con-
nected to inflammation underlined by the works of other
authors as for example Varoga and Paulsen who investi-
gated both mediators in the cause of chronic inflamma-
tion of joint tissues as seen in osteoarthritis or rheumatoid
arthritis [8,14,15].
There is evidence of a cancer specific loss of hBD-1 in 90%
of renal clear cell carcinoma and 82% of malignant pros-
tate cancer [10]. In squamous cell carcinomas of the oral
cavity we found a 50-fold decreased gene expression of
hBD-1 compared to healthy gingiva. In benign lesions of
the oral mucosa as irritation fibromas or leukoplakias the
hBD-1 gene expression was also decreased (5-fold in irri-
tation fibroma and 2.5-fold in leukoplakia). These obser-
vations underline the hypothesis that hBD-1 might
function as tumour suppressor gene and thus play a key
role in the malignant progression of epithelial tumours
[11]. Nevertheless the hBD-1 protein was detected mostly
in the nucleus of the malignant salivary gland tumours.
Therefore it is surprising, that the protein accumulates in
the nucleus although the gene might be down regulated.
Maybe by nuclear accumulation the hBD-1 protein down-
regulates its own promoter. Promoter autoregulation is a
well known effect and has been reported for other pro-
teins before [16].
Loss of p53 tumour suppressor gene function is one of the
most common genetic events described in human cancer
[17]. Immunohistochemical staining for p53 usually
shows mutant-type of p53, because the half-life of wild-
type p53 protein is too short to detect. Wild-type p53 con-
tributes to tumour suppression through at least two mech-
anisms: In response to DNA damage p53 causes the arrest
of cell proliferation and/or the induction of apoptosis
[18-20]. It has been suggested that p53 may induce apop-
totic cell death by down-regulating bcl-2 and up-regulat-
ing bax expression [21,22].
The loss of p53 tumour suppressor function leading to
deregulations in the apoptotic pathway might cause resist-
ance of certain tumour cells to chemotherapy and radio-
therapy [23].
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In this study, an interrelation between hBD-1 and p53 as
tumour suppressor or bcl-2 as proto-oncogene, was not
evident. This might be, for different entities of salivary
gland tumours were investigated to underline the effect of
the hBD-1-translocation in malignant tumours versus
healthy salivary gland tissue or benign tumours. P53 for
instance is known to be undetectable in mucoepidermoid
carcinomas [2]. The traceability of the presently known
tumour-suppressor- or proto-onco-genes might be related
to the tumour entity, whereas nuclear accumulation of the
hBD-1 seems to be independent from the tumour entity,
but related to malignancy.
Table 1: Location of hBD-1, -2, -3, p53 and bcl-2 in malignant, benign and healthy salivary gland tissues (positive ++, weak positive +, 
negative -)
tumour behaviour hBD-1 hBD-2 hBD-3 bcl-2 p53
salivary duct carcinoma malignant nucleus (and cytoplasm+) cytoplasm++ cytoplasm ++ negative- positive+
mucoepidermoid 
carcinoma
malignant nucleus++ 
(and cytoplasm+)
cytoplasm++ cytoplasm++ positive++ positive+
adenoid cystic 
carcinoma
malignant nucleus++ cytoplasm++ cytoplasm++ and nucleus+ negative- positive+
adenoid cystic 
carcinoma
malignant nucleus++ cytoplasm++ cytoplasm++ negative- negative
adenoid cystic 
carcinoma
malignant nucleus++ cytoplasm++ cytoplasm++ negative- negative
carcinosarcoma malignant nucleus++ cytoplasm++ cytoplasm++ positive++ positive+
adenocarcinoma malignant nucleus++ cytoplasm++ cytoplasm++ positive++ positive+
pleomorphic adenoma benign cytoplasm++ 
(and nucleus+)
cytoplasm++ cytoplasm++ positive++ negative
pleomorphic adenoma benign cytoplasm++ 
(and nucleus+)
cytoplasm++ cytoplasm++ positive++ negative
pleomorphic adenoma benign cytoplasm++ 
(and nucleus+)
cytoplasm++ cytoplasm++ positive++ negative
cystadenolymphoma benign cytoplasm++ cytoplasm cytoplasm++ negative- negative
cystadenolymphoma benign cytoplasm++ cytoplasm cytoplasm++ positive++ negative
oncocytoma benign cytoplasm++ cytoplasm cytoplasm++ positive++ weak positive+
oncocytoma benign cytoplasm++ cytoplasm++ cytoplasm++ positive++ weak positive+
healthy salvary gland 
tissue 1
healthy cytoplasm++ cytoplasm+ cytoplasm++ negative- negative
healthy salvary gland 
tissue 2
healthy cytoplasm++ cytoplasm++ cytoplasm++ negative- negative
healthy salvary gland 
tissue 3
healthy cytoplasm+ cytoplasm++ cytoplasm++ negative- negative
healthy salvary gland 
tissue 4
healthy cytoplasm++ cytoplasm+ cytoplasm++ negative- negative
healthy salvary gland 
tissue 5
healthy cytoplasm++ cytoplasm+ cytoplasm++ negative- negative
healthy salvary gland 
tissue 6
healthy cytoplasm++ cytoplasm++ cytoplasm+ negative- negative
healthy salvary gland 
tissue 7
healthy cytoplasm++ cytoplasm++ cytoplasm++ negative- negative
Table 2: Cellular Localization of hBD-1, -2 and -3 in malignant salivary gland tumours in comparison with healthy salivary gland tissue
hBD-1 hBd-2 hBD-3
Total Number of Cells Nuclear Staining % Nuclear Staining % Nuclear Staining %
Healthy 700 22 3 62 9 31 4
Malignant 700 525 75 88 13 302 43
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Sherman and Froy reported that hBD-1 expression is up-
regulated by c-myc expression, suggesting that c-myc reg-
ulates hBD-1 expression via a non-inflammatory pathway
[24]. As c-myc is implicated in human cancers, and over-
expression of c-myc at the protein and/or mRNA levels
has been observed in virtually all types of cancers [25] a
hBD-1 involving pathway might play a role in cancero-
genesis.
There have been recent reports that the hBD-1 sequence
shows homology with known cationic nuclear localized
signal sequences in human keratinocytes. Furthermore
nuclear localization of hBD-1 in human keratinocytes was
described, which suggests a role for this peptide in gene
expression [26]. The reason and biological impact of its
nuclear translocation in malignant salivary gland tumours
is not clear. Further studies should investigate whether
hBD-1 protein accumulation is related to a down-regula-
tion of hBD-1 gene expression as it was described in renal
clear cell carcinoma or malignant prostate cancer [10]. We
have the hypothesis that hBD-1 has abilities of a tumour
suppressor gene. Nuclear accumulation of hBD-1 protein
could be involved in the malignant progression of salivary
gland tumours.
Pleomorphic adenomas are benign mixed tumours. They
represent the most common neoplasms of the major sali-
vary glands. It is not uncommon for pleomorphic adeno-
mas to recur, and, though benign a subset will undergo
malignant transformation [27]. As there was cytoplasmic
as well as weak nuclear hBD-1 staining in the investigated
pleomorphic adenomas in this study, this observation
might underline the role of nuclear hBD-1 translocation
in the ability of these tumours to recur or undergo a malig-
nant transformation and should be observed in a greater
subset of pleomorphic adenomas.
Conclusion
1. HBD-1, -2 and -3 is traceable in benign as well as malig-
nant tumours of the salivary glands.
2. We hypothesize that the nuclear shift of hBD-1 might
be associated with malignancy in these tumours.
3. Pleomorphic adenomas show nuclear as well as cyto-
plasmatic hBD-1 staining which might be connected to
their biologic behaviour of recurrence and malignant
transformation.
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hBD 1 staining in healthy salivary gland tissue (A) and adenoid cystic carcinoma (B)Figure 1
hBD 1 staining in healthy salivary gland tissue (A) and 
adenoid cystic carcinoma (B).
 
hBD-2 staining in healthy salivary gland tissue (above) and adenoid cystic carcinoma (below)Figure 2
hBD-2 staining in healthy salivary gland tissue 
(above) and adenoid cystic carcinoma (below).
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